
Medtronic (MDT) Stock Forecast & Price Target
Medtronic (MDT) Analyst Ratings
Bulls say
Medtronic is a profitable, innovative company with strong potential for growth due to its successful Symplicity Spyral product, separation of its Diabetes business, potential for expansion into new markets, and a promising pipeline of products. However, there are risks to watch out for, such as unsuccessful product launches and fluctuations in the economy and currency. Overall, the stock has a positive outlook, with a Buy rating and a strong potential for long-term growth and value for investors.
Bears say
Medtronic is facing multiple challenges that make it unlikely the company will see a significant increase in stock price in the near future. Despite having a broad portfolio and several key growth drivers, MDT has consistently underperformed in terms of revenue and earnings growth. In addition, the company's high reliance on government reimbursement programs and potential competitive risks could further hinder its growth and profitability. MDT also faces potential risks related to capital allocation and the performance of its recent M&A activities. Overall, we see limited upside for Medtronic's stock in the current market environment.
This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.
Medtronic (MDT) Analyst Forecast & Price Prediction
Start investing in Medtronic (MDT)
Order type
Buy in
Order amount
Est. shares
0 shares